Adding Palbociclib Delays Progression in HR-Positive Breast Cancer

June 2, 2015
Nicholas C. Turner, MD

In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.

In this video, Nicholas C. Turner, MD, of Royal Marsden Hospital and the Cancer Research Institute in London, discusses the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor (HR)-positive HER2-negative breast cancer.

Related Content:

ASCO | Conference